

Lars Bastholt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/228943/publications.pdf>

Version: 2024-02-01

125
papers

21,989
citations

53660

45
h-index

16605

123
g-index

127
all docs

127
docs citations

127
times ranked

25163
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
2	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
3	Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2014, 384, 319-328.	6.3	1,295
4	Tertiary lymphoid structures improve immunotherapy and survival in melanoma. <i>Nature</i> , 2020, 577, 561-565.	13.7	1,209
5	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
6	Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. <i>Lancet, The</i> , 2003, 362, 933-940.	6.3	626
7	A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. <i>Radiotherapy and Oncology</i> , 1998, 46, 135-146.	0.3	523
8	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204.	1.8	500
9	Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer. <i>New England Journal of Medicine</i> , 2008, 359, 31-42.	13.9	446
10	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 611-622.	5.1	428
11	Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 1989-2007.	1.3	404
12	Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. <i>European Journal of Cancer</i> , 2019, 118, 10-34.	1.3	345
13	Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3794-3801.	0.8	337
14	Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. <i>Lancet Oncology, The</i> , 2012, 13, 897-905.	5.1	331
15	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	1.3	330
16	Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. <i>European Journal of Cancer</i> , 2015, 51, 2396-2403.	1.3	320
17	Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 555-567.	3.2	267
18	Osteoradionecrosis of the jaws: Clinical characteristics and relation to the field of irradiation. <i>Journal of Oral and Maxillofacial Surgery</i> , 2000, 58, 1088-1093.	0.5	244

#	ARTICLE	IF	CITATIONS
19	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224
20	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. <i>European Journal of Cancer</i> , 2020, 128, 83-102.	1.3	181
21	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment " Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	1.3	154
22	Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation. <i>Radiotherapy and Oncology</i> , 1997, 43, 47-51.	0.3	133
23	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics " Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 141-158.	1.3	133
24	European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. <i>European Journal of Cancer</i> , 2020, 128, 60-82.	1.3	131
25	Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2005, 23, 5117-5125.	0.8	114
26	Influence of Late Side-Effects Upon Daily Life After Radiotherapy for Laryngeal and Pharyngeal Cancer. <i>Acta OncolÅ³gica</i> , 1994, 33, 487-491.	0.8	102
27	The Feasibility of High Dose Iodine 131 Treatment as an Alternative to Surgery in Patients with a Very Large Goiter: Effect on Thyroid Function and Size and Pulmonary Function*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3636-3641.	1.8	102
28	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	1.3	102
29	Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 144-152.	5.1	93
30	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	1.3	92
31	Salvage laryngectomy and pharyngocutaneous fistulae after primary radiotherapy for head and neck cancer: A national survey from DAHANCA. <i>Head and Neck</i> , 2003, 25, 711-716.	0.9	88
32	Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3831-3837.	0.8	88
33	Improvement of Goiter Volume Reduction after 0.3 mg Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy in Patients with a Very Large Goiter: A Double-Blinded, Randomized Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3424-3428.	1.8	82
34	The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. <i>European Journal of Cancer</i> , 2017, 74, 89-95.	1.3	77
35	Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant Interferon. <i>Journal of the National Cancer Institute</i> , 2009, 101, 869-877.	3.0	72
36	Interleukin-6 and melanoma. <i>Melanoma Research</i> , 2012, 22, 327-333.	0.6	70

#	ARTICLE	IF	CITATIONS
37	Hypopharyngeal Cancer: Results of Treatment Based on Radiation Therapy and Salvage Surgery. <i>Laryngoscope</i> , 2002, 112, 834-838.	1.1	67
38	Cancer of the Larynx: Treatment Results after Primary Radiotherapy with Salvage Surgery in a Series of 1005 Patients. <i>Acta Oncologica</i> , 2002, 41, 69-76.	0.8	66
39	Papillary Thyroid Carcinoma in Denmark, 1996â€“2008: Outcome and Evaluation of Established Prognostic Scoring Systems in a Prospective National Cohort. <i>Thyroid</i> , 2015, 25, 78-84.	2.4	59
40	Papillary Thyroid Microcarcinoma in Denmark 1996â€“2008: A National Study of Epidemiology and Clinical Significance. <i>Thyroid</i> , 2013, 23, 1159-1164.	2.4	57
41	A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 465-469.	1.1	55
42	Lymph Node Metastases from Laryngeal and Pharyngeal Carcinomas: Calculation of Burden of Metastasis and its Impact on Prognosis. <i>Acta Oncologica</i> , 1998, 37, 489-493.	0.8	50
43	Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Large Nodular Goiters Facilitates Tracheal Decompression and Improves Inspiration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3981-3984.	1.8	48
44	Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 287-293.	0.6	48
45	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	0.8	48
46	The real-world impact of modern treatments on the survival of patients with metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 108, 25-32.	1.3	47
47	Recombinant Human Thyrotropin-Stimulated Radioiodine Therapy of Nodular Goiter Allows Major Reduction of the Radiation Burden with Retained Efficacy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 3719-3725.	1.8	43
48	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1424674.	2.1	43
49	Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFR (HuMax-EGFR) in patients with advanced squamous cell carcinoma of the head and neck. <i>Radiotherapy and Oncology</i> , 2007, 85, 24-28.	0.3	41
50	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
51	Prognostic Factors in Papillary and Follicular Thyroid Carcinomas. <i>Laryngoscope</i> , 1998, 108, 243-249.	1.1	37
52	Does Radioiodine Therapy Have an Equal Effect on Substernal and Cervical Goiter Volumes? Evaluation by Magnetic Resonance Imaging. <i>Thyroid</i> , 2002, 12, 313-317.	2.4	37
53	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	1.7	37
54	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664.	5.1	37

#	ARTICLE	IF	CITATIONS
55	Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 63-68.	1.1	36
56	Prestimulation with Recombinant Human Thyrotropin (rhTSH) Improves the Long-Term Outcome of Radioiodine Therapy for Multinodular Nontoxic Goiter. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2653-2660.	1.8	36
57	Papillary thyroid carcinoma in Denmark 1996-2008: An investigation of changes in incidence. <i>Cancer Epidemiology</i> , 2013, 37, e1-e6.	0.8	35
58	Duration of symptoms: Impact on outcome of radiotherapy in glottic cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 789-794.	0.4	33
59	Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2773-2781.	0.8	33
60	Osseointegrated Implants for Prosthetic Rehabilitation after Treatment of Cancer of the Oral Cavity. <i>Acta Oncologica</i> , 1997, 36, 37-40.	0.8	32
61	Multiple endocrine neoplasia type 2: A review. <i>Seminars in Cancer Biology</i> , 2022, 79, 163-179.	4.3	32
62	Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). <i>Journal of Clinical Oncology</i> , 2022, 40, 1870-1878.	0.8	29
63	The Danish national guidelines for treatment of oral squamous cell carcinoma. <i>Acta Oncologica</i> , 2006, 45, 294-299.	0.8	28
64	Prognostic Stratification of Ulcerated Melanoma. <i>American Journal of Clinical Pathology</i> , 2014, 142, 845-856.	0.4	28
65	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	1.3	27
66	Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 627-634.	2.3	25
67	Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. <i>Oncology</i> , 2013, 2, e23288.	2.1	25
68	Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences. <i>Journal of Medical Internet Research</i> , 2020, 22, e14896.	2.1	24
69	CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis. <i>Journal of Investigative Dermatology</i> , 2012, 132, 299-303.	0.3	23
70	Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4-4.	0.8	23
71	A phase II trial of low-dose total body irradiation and subcutaneous Interleukin-2 in metastatic melanoma. <i>Radiotherapy and Oncology</i> , 2005, 77, 143-147.	0.3	22
72	Papillary microcarcinoma of the thyroid gland: Is the immunohistochemical expression of cyclin D1 or galectin-3 in primary tumour an indicator of metastatic disease?. <i>Acta Oncologica</i> , 2008, 47, 451-457.	0.8	22

#	ARTICLE	IF	CITATIONS
73	Prognostic and predictive value of YKL-40 in stage IIB-III melanoma. <i>Melanoma Research</i> , 2016, 26, 367-376.	0.6	22
74	A phase II study of thalidomide in patients with brain metastases from malignant melanoma. <i>Acta Oncologica</i> , 2008, 47, 1526-1530.	0.8	21
75	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21
76	Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer; A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age. <i>Breast Cancer Research and Treatment</i> , 2000, 61, 103-110.	1.1	20
77	Completeness and validity in a national clinical thyroid cancer database: DATHYRCA. <i>Cancer Epidemiology</i> , 2014, 38, 633-637.	0.8	20
78	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	0.9	19
79	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168.	1.3	19
80	The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 35, 45-52.	1.1	18
81	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	0.9	17
82	A Placebo-Controlled, Blinded and Randomised Study on the Effects of Recombinant Human Thyrotropin on Quality of Life in the Treatment of Thyroid Cancer. <i>European Thyroid Journal</i> , 2013, 2, 195-202.	1.2	16
83	Danish translation, cultural adaption and initial psychometric evaluation of the patient feedback form. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 77.	1.0	14
84	Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 6060-6060.	0.8	14
85	The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. <i>Melanoma Research</i> , 2018, 28, 333-340.	0.6	13
86	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	1.3	13
87	High-dose platinum chemotherapy in advanced ovarian cancer: A phase II study. <i>Gynecologic Oncology</i> , 1992, 44, 79-82.	0.6	12
88	Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 349-355.	2.0	12
89	The Prognostic Role of Blood Lymphocyte Subset Distribution in Patients With Resected High-risk Primary or Regionally Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2007, 30, 773-779.	1.2	11
90	Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma. <i>Acta Oncologica</i> , 2013, 52, 1086-1093.	0.8	11

#	ARTICLE	IF	CITATIONS
91	Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. <i>Melanoma Research</i> , 2013, 23, 21-26.	0.6	11
92	MelanA-negative spindle-cell associated melanoma, a distinct inflammatory phenotype correlated with dense infiltration of CD163 macrophages and loss of E-cadherin. <i>Melanoma Research</i> , 2015, 25, 113-118.	0.6	11
93	Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 44-53.	0.5	11
94	Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer. <i>European Thyroid Journal</i> , 2016, 5, 187-194.	1.2	11
95	High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. <i>European Journal of Cancer</i> , 2019, 115, 61-67.	1.3	11
96	A pharmacokinetic study of prednimustine as compared with prednisolone plus chlorambucil in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 205-210.	1.1	10
97	Melanoma Early Detection and Awareness. <i>American Journal of Therapeutics</i> , 2015, 22, 37-43.	0.5	10
98	The role of FDG-PET/CT in preoperative staging of sentinel lymph node biopsy-positive melanoma patients. <i>EJNMMI Research</i> , 2016, 6, 73.	1.1	10
99	Pazopanib-Induced Hypertension in Patients With Renal Cell Carcinoma Is Associated With Low Urine Excretion of NO Metabolites. <i>Hypertension</i> , 2018, 71, 473-480.	1.3	10
100	Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication. <i>Anticancer Research</i> , 2016, 36, 749-56.	0.5	10
101	Large Discrepancy in the Results of Sensitive Measurements of Thyroglobulin Antibodies in the Follow-Up on Thyroid Cancer: A Diagnostic Dilemma. <i>European Thyroid Journal</i> , 2012, 1, 193-197.	1.2	9
102	Benefit of adjuvant interferon alfa-2b (IFN- α 2b) therapy in melanoma patients with high serum MMP-8 levels. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 173-180.	2.0	9
103	Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. <i>Acta Oncologica</i> , 2017, 56, 109-110.	0.8	9
104	The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous. <i>International Journal of Cancer</i> , 2019, 145, 3173-3174.	2.3	9
105	Weekly Oral Idarubicin in Advanced Prostatic Cancer A Phase II Study. <i>Acta Oncologica</i> , 1992, 31, 337-340.	0.8	8
106	Total Thyroidectomy for Thyroid Cancer Followed by Thyroid Storm due to Thyrotropin Receptor Antibody Stimulation of Metastatic Thyroid Tissue. <i>European Thyroid Journal</i> , 2017, 6, 276-280.	1.2	8
107	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2591.	1.7	8
108	The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994, 34, 439-443.	1.1	7

#	ARTICLE	IF	CITATIONS
109	Consumption of the Epidermis. American Journal of Dermatopathology, 2015, 37, 841-845.	0.3	7
110	Loss of E-cadherin as Part of a Migratory Phenotype in Melanoma Is Associated With Ulceration. American Journal of Dermatopathology, 2017, 39, 672-678.	0.3	7
111	A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209.. Journal of Clinical Oncology, 2018, 36, 6021-6021.	0.8	7
112	Impact of patient-reported outcomes on symptom monitoring during treatment with checkpoint inhibitors: health-related quality of life among melanoma patients in a randomized controlled trial. Journal of Patient-Reported Outcomes, 2022, 6, 8.	0.9	7
113	Trends in melanoma in the elderly in Denmark, 1980â€“2012. Acta OncolÃ³gica, 2016, 55, 52-58.	0.8	6
114	Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial.. Journal of Clinical Oncology, 2014, 32, 6061-6061.	0.8	6
115	The diagnostic accuracy and clinical impact of FDG-PET/CT follow-up for patients on adjuvant immunotherapy for high-risk malignant melanoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2342-2351.	3.3	6
116	Stabilization of circulating thyroglobulin mRNA transcripts in patients treated for differentiated thyroid carcinoma. Annals of Clinical Biochemistry, 2017, 54, 558-566.	0.8	5
117	Comment on â€œDiagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 131, 100-103.	1.3	4
118	Genetic predisposition to long telomeres is associated with increased mortality after melanoma: A study of 2101 melanoma patients from hospital clinics and the general population. Pigment Cell and Melanoma Research, 2021, 34, 946-954.	1.5	4
119	Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study. Cancers, 2021, 13, 5550.	1.7	4
120	Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial. Cancer Immunology, Immunotherapy, 2015, 64, 769-776.	2.0	3
121	Measured and genetically predicted plasma YKL-40 levels and melanoma mortality. European Journal of Cancer, 2019, 121, 74-84.	1.3	3
122	A phase II study using vinorelbine and continuous 5-fluorouracil in patients with advanced head and neck cancer. Acta OncolÃ³gica, 2007, 46, 374-377.	0.8	2
123	Response to: Comment on â€œDiagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelinesâ€™. European Journal of Cancer, 2020, 140, 154-157.	1.3	1
124	Serum IL-6 as a prognostic biomarker in patients with stage IIB-III melanoma.. Journal of Clinical Oncology, 2012, 30, 8545-8545.	0.8	0
125	Immunotherapy in Patients with mCRC. , 2021, , 183-186.		0